Shanghai Pharmaceuticals Holding Co Ltd Class H (HK:2607)
:2607
2607 Stock Chart & Stats
HK$11.91
-HK$0.08(-0.65%)
At close: 4:00 PM EST
HK$11.91
-HK$0.08(-0.65%)
Day’s Range― - ―
52-Week RangeHK$10.18 - HK$13.12
Previous CloseN/A
Volume2.05M
Average Volume (3M)2.90M
Market Cap
HK$66.03B
Enterprise ValueHK$80.83B
Total Cash (Recent Filing)HK$43.08B
Total Debt (Recent Filing)HK$49.48B
Price to Earnings (P/E)6.6
Beta0.69
Next Earnings
Apr 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.67%
Share Statistics
EPS (TTM)0.18
Shares Outstanding919,072,700
10 Day Avg. Volume2,690,085
30 Day Avg. Volume2,904,360
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)0.50
Price to Sales (P/S)0.13
P/FCF Ratio9.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.43
Revenue Forecast (FY)HK$300.60B
Bulls Say, Bears Say
Bulls Say
Diversified Business ModelThe firm operates both large-scale distribution and drug manufacturing, giving diversified revenue streams and cross-selling opportunities across hospitals, pharmacies and logistics. This reduces single-segment dependency and supports stable structural cashflow and customer stickiness over months to years.
Scale And Expanding Equity/assetsSignificant balance-sheet scale and rising equity indicate capacity to invest in distribution footprint, cold-chain and manufacturing. Larger asset base bolsters supplier negotiating power, logistics reach and resilience to shocks, supporting durable market positioning and ability to pursue strategic investments.
Improving Earnings And Positive Free Cash FlowEarnings rebound and positive FCF signal improved underlying profitability and ability to self-fund working capital, capex or deleveraging. Sustained positive operating cash flow provides longer-term flexibility to support distribution logistics and manufacturing investments despite cyclical swings.
Bears Say
Sharply Slowing Revenue GrowthA sharp deceleration to ~1% top-line growth reduces forward operating leverage and limits scope for margin recovery. Slower organic demand intensifies competitive pressure, weakens bargaining leverage on procurement and may constrain long-term reinvestment and scale benefits if the trend persists.
Structural Margin CompressionSustained decline in gross margins points to structural pricing or product-mix pressure in distribution and manufacturing. Thin margins limit earnings sensitivity to volume growth and reduce capacity to absorb cost inflation, restricting long-term ROE improvement and capital allocation flexibility.
Uneven Cash Conversion And Volatile FCFPersistent working-capital absorption and volatile FCF weaken the link between reported profits and available cash. This constrains debt reduction, dividends or strategic M&A, raising execution risk on long-term growth plans and making the balance sheet more sensitive to cyclical shocks.
Shanghai Pharmaceuticals Holding Co News
2607 FAQ
What was Shanghai Pharmaceuticals Holding Co Ltd Class H’s price range in the past 12 months?
Shanghai Pharmaceuticals Holding Co Ltd Class H lowest stock price was HK$10.18 and its highest was HK$13.12 in the past 12 months.
What is Shanghai Pharmaceuticals Holding Co Ltd Class H’s market cap?
Shanghai Pharmaceuticals Holding Co Ltd Class H’s market cap is HK$66.03B.
When is Shanghai Pharmaceuticals Holding Co Ltd Class H’s upcoming earnings report date?
Shanghai Pharmaceuticals Holding Co Ltd Class H’s upcoming earnings report date is Apr 30, 2026 which is in 22 days.
How were Shanghai Pharmaceuticals Holding Co Ltd Class H’s earnings last quarter?
Shanghai Pharmaceuticals Holding Co Ltd Class H released its earnings results on Mar 29, 2026. The company reported HK$0.178 earnings per share for the quarter, missing the consensus estimate of HK$0.223 by -HK$0.045.
Is Shanghai Pharmaceuticals Holding Co Ltd Class H overvalued?
According to Wall Street analysts Shanghai Pharmaceuticals Holding Co Ltd Class H’s price is currently Overvalued.
Does Shanghai Pharmaceuticals Holding Co Ltd Class H pay dividends?
Shanghai Pharmaceuticals Holding Co Ltd Class H pays a Notavailable dividend of HK$0.317 which represents an annual dividend yield of 2.67%. See more information on Shanghai Pharmaceuticals Holding Co Ltd Class H dividends here
What is Shanghai Pharmaceuticals Holding Co Ltd Class H’s EPS estimate?
Shanghai Pharmaceuticals Holding Co Ltd Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Pharmaceuticals Holding Co Ltd Class H have?
Shanghai Pharmaceuticals Holding Co Ltd Class H has 919,072,700 shares outstanding.
What happened to Shanghai Pharmaceuticals Holding Co Ltd Class H’s price movement after its last earnings report?
Shanghai Pharmaceuticals Holding Co Ltd Class H reported an EPS of HK$0.178 in its last earnings report, missing expectations of HK$0.223. Following the earnings report the stock price went up 0.735%.
Which hedge fund is a major shareholder of Shanghai Pharmaceuticals Holding Co Ltd Class H?
Currently, no hedge funds are holding shares in HK:2607
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Pharmaceuticals Holding Co Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.71%
12-Months-Change
Fundamentals
Return on Equity
7.64%
Trailing 12-Months
Asset Growth
10.07%
Trailing 12-Months
Company Description
Shanghai Pharmaceuticals Holding Co Ltd Class H
Shanghai Pharmaceuticals Holding Co., Ltd., an investment holding company, researches, develops, manufactures, distributes, and retails pharmaceutical and healthcare products in the People's Republic of China. It operates through four segments: Production, Distribution, Retail, and Others. The company offers chemicals and biochemicals, Chinese medicines, healthcare products, and medical devices in various therapeutic areas, including oncology, cerebrocardiovascular, CNS, general infection, immunology, digestive and metabolism, and respiratory. It provides approximately 700 varieties of drugs. The company also engages in the provision of pharmaceutical distribution, warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it engages in the operation of a network of retail pharmacy stores; online drug business; and provision of consulting services, assets management operations, as well as clinical trials, medical aid, physicians and patients' education, e-prescription management, and remote and cloud hospitals. Further, the company manufactures and trades in medicines. It operates approximately 2,000 retail chain pharmacies in 24 provinces. The company was incorporated in 1994 and is headquartered in Shanghai, the People's Republic of China. Shanghai Pharmaceuticals Holding Co., Ltd. is a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd.
Technical Analysis
Sinopharm Group Co
―
IVD Medical Holding Limited
―
Charmacy Pharmaceutical Co., Ltd. Class H
―
Options Prices
Currently, No data available
---